Biocon says it is moving from an expansion phase to a focus on capacity utilization, margin expansion, and stronger returns. After major investments to build global capabilities, the company reported 13% revenue growth for FY26, but net profit fell significantly. Biocon is also aiming for sustainable profitable growth while exploring in-licensing for its biosimilars portfolio.
Biocon’s fourth-quarter net profit fell 63% year-on-year, driven by exceptional one-off charges that weighed on the numbers. Despite the shock, the company’s core businesses expanded, supported by the integration of its biosimilars and generics operations. The firm said it will focus on improving profitability and delivering long-term value, recommending a final dividend of Rs 0.50.
Your news, in seconds
Get the Beige app — every story in 60 words, updated hourly. Free on iOS & Android.
Biocon founder Kiran Mazumdar-Shaw has reportedly named her niece, Claire Mazumdar, as the company’s successor. Claire, founder and CEO of Bicara Therapeutics, brings advanced qualifications and prior industry experience. The announcement also comes amid broader structural and leadership changes across Biocon group firms as it pushes biosimilars and deeper artificial intelligence integration.
Aurobindo Pharma said its subsidiary CuraTeQ Biologics has received a compliance notice from Health Canada for its cancer biosimilar Bevqolva, a bevacizumab-based treatment used across multiple cancers. The development signals Health Canada’s confirmation of safety and efficacy, paving the way for broader access to potential cost-effective options for patients in Canada.
Dr Reddy’s has received regulatory approval in India to roll out its generic oral semaglutide. The approval follows a head to head comparative study in India that found the formulation non inferior to Novo Nordisk’s Rybelsus. The company says this clinical evidence helped it secure approval under India’s biosimilar regulatory pathway.
Swipe through stories, personalise your feed, and save articles for later — all on the app.
